NMRA Neumora Therapeutics: רווח למניה בשנים עשר החודשים האחרונים

Neumora Therapeutics (NMRA) develops proprietary therapies for psychiatric disorders utilizing AI-driven biomarker analysis. A key competitive advantage is the data science approach to patient selection based on neural profiles, which enhances treatment precision. Growth is driven by the expansion of a clinic network focused on combating depression. This TTM earnings per share chart confirms the asset balance, where the -1.07 level serves as a critical benchmark for assessing investment attractiveness.
פילוחים אנליטיים של חברת Neumora Therapeutics (NMRA)

Earnings per share (EPS TTM) measures the owner's share of the final financial result by dividing the total annual income by the number of common shares. By analyzing the rolling net income per share trend, recorded at -1.07, an investor sees a reflection of the clinical development stage of Neumora Therapeutics (NMRA), where the absence of commercial sales and R&D expenses drive the metric's negative trend.